BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bosello S, De Santis M, Lama G, Spanò C, Angelucci C, Tolusso B, Sica G, Ferraccioli G. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther. 2010;12:R54. [PMID: 20338043 DOI: 10.1186/ar2965] [Cited by in Crossref: 122] [Cited by in F6Publishing: 101] [Article Influence: 11.1] [Reference Citation Analysis]
Number Citing Articles
1 Jordan S, Distler JH, Maurer B, Huscher D, van Laar JM, Allanore Y, Distler O. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis. 2015;74:1188-1194. [PMID: 24442885 DOI: 10.1136/annrheumdis-2013-204522] [Cited by in Crossref: 226] [Cited by in F6Publishing: 195] [Article Influence: 32.3] [Reference Citation Analysis]
2 Aringer M, Denton CP. Systemic sclerosis phase III clinical trials: Hope on the horizon? Journal of Scleroderma and Related Disorders 2018;3:193-200. [DOI: 10.1177/2397198318775353] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
3 Moinzadeh P, Denton C, Abraham D, Ong V, Hunzelmann N, Eckes B, Krieg T. Biomarkers for skin involvement and fibrotic activity in scleroderma: Fibrosis-biomarkers in SSc. Journal of the European Academy of Dermatology and Venereology 2012;26:267-76. [DOI: 10.1111/j.1468-3083.2011.04206.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
4 Vilela VS, Maretti GB, Silva Gama LMD, Costa CHD, Rufino RL, Levy RA. Tratamento da esclerose sistêmica com rituximabe: uma série de 10 casos em centro único. Revista Brasileira de Reumatologia 2016;56:458-63. [DOI: 10.1016/j.rbr.2016.04.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
5 Moradzadeh M, Aghaei M, Mehrbakhsh Z, Arab-Bafrani Z, Abdollahi N. Efficacy and safety of rituximab therapy in patients with systemic sclerosis disease (SSc): systematic review and meta-analysis. Clin Rheumatol 2021. [PMID: 33796953 DOI: 10.1007/s10067-021-05698-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Giacomelli R, Liakouli V, Berardicurti O, Ruscitti P, Di Benedetto P, Carubbi F, Guggino G, Di Bartolomeo S, Ciccia F, Triolo G, Cipriani P. Interstitial lung disease in systemic sclerosis: current and future treatment. Rheumatol Int 2017;37:853-63. [PMID: 28063071 DOI: 10.1007/s00296-016-3636-7] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 10.3] [Reference Citation Analysis]
7 Yanaba K. Strategy for treatment of fibrosis in systemic sclerosis: Present and future. J Dermatol 2016;43:46-55. [PMID: 26782006 DOI: 10.1111/1346-8138.13026] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
8 Matsushita T, Kobayashi T, Mizumaki K, Kano M, Sawada T, Tennichi M, Okamura A, Hamaguchi Y, Iwakura Y, Hasegawa M, Fujimoto M, Takehara K. BAFF inhibition attenuates fibrosis in scleroderma by modulating the regulatory and effector B cell balance. Sci Adv 2018;4:eaas9944. [PMID: 30009261 DOI: 10.1126/sciadv.aas9944] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 14.0] [Reference Citation Analysis]
9 Topal AA, Dhurat RS. Scleroderma therapy: clinical overview of current trends and future perspective. Rheumatol Int 2013;33:1-18. [PMID: 23011088 DOI: 10.1007/s00296-012-2486-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
10 Leask A. Emerging targets for the treatment of scleroderma. Expert Opinion on Emerging Drugs 2012;17:173-9. [DOI: 10.1517/14728214.2012.678833] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
11 Varjú C, Péntek M, Lóránd V, Nagy G, Minier T, Czirják L. Musculoskeletal Involvement in Systemic Sclerosis: An Unexplored Aspect of the Disease. Journal of Scleroderma and Related Disorders 2017;2:19-32. [DOI: 10.5301/jsrd.5000228] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 2.6] [Reference Citation Analysis]
12 Yasuoka H. Recent Treatments of Interstitial Lung Disease with Systemic Sclerosis. Clin Med Insights Circ Respir Pulm Med 2015;9:97-110. [PMID: 26819563 DOI: 10.4137/CCRPM.S23315] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
13 Barnes TC, Anderson ME, Moots RJ. The many faces of interleukin-6: the role of IL-6 in inflammation, vasculopathy, and fibrosis in systemic sclerosis. Int J Rheumatol 2011;2011:721608. [PMID: 21941555 DOI: 10.1155/2011/721608] [Cited by in Crossref: 132] [Cited by in F6Publishing: 133] [Article Influence: 13.2] [Reference Citation Analysis]
14 Bosello S, De Luca G, Tolusso B, Lama G, Angelucci C, Sica G, Ferraccioli G. B cells in systemic sclerosis: a possible target for therapy. Autoimmun Rev 2011;10:624-30. [PMID: 21545850 DOI: 10.1016/j.autrev.2011.04.013] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 4.8] [Reference Citation Analysis]
15 Daoussis D, Tsamandas A, Antonopoulos I, Filippopoulou A, Papachristou DJ, Papachristou NI, Andonopoulos AP, Liossis SN. B cell depletion therapy upregulates Dkk-1 skin expression in patients with systemic sclerosis: association with enhanced resolution of skin fibrosis. Arthritis Res Ther 2016;18:118. [PMID: 27208972 DOI: 10.1186/s13075-016-1017-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
16 Asano Y, Varga J. Rationally-based therapeutic disease modification in systemic sclerosis: Novel strategies. Semin Cell Dev Biol 2020;101:146-60. [PMID: 31859147 DOI: 10.1016/j.semcdb.2019.12.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
17 Sumida H, Asano Y, Tamaki Z, Aozasa N, Taniguchi T, Takahashi T, Toyama T, Ichimura Y, Noda S, Akamata K, Miyazaki M, Kuwano Y, Yanaba K, Sato S. Successful experience of rituximab therapy for systemic sclerosis-associated interstitial lung disease with concomitant systemic lupus erythematosus. J Dermatol 2014;41:418-20. [PMID: 24801917 DOI: 10.1111/1346-8138.12461] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
18 Narváez J, LLuch J, Molina-Molina M, Vicens-Zygmunt V, Luburich P, Yañez MA, Nolla JM. Rituximab as a rescue treatment added on mycophenolate mofetil background therapy in progressive systemic sclerosis associated interstitial lung disease unresponsive to conventional immunosuppression. Semin Arthritis Rheum 2020;50:977-87. [PMID: 32911289 DOI: 10.1016/j.semarthrit.2020.08.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
19 Mavropoulos A, Simopoulou T, Varna A, Liaskos C, Katsiari CG, Bogdanos DP, Sakkas LI. Breg Cells Are Numerically Decreased and Functionally Impaired in Patients With Systemic Sclerosis: BREG CELLS IN SYSTEMIC SCLEROSIS. Arthritis & Rheumatology 2016;68:494-504. [DOI: 10.1002/art.39437] [Cited by in Crossref: 74] [Cited by in F6Publishing: 70] [Article Influence: 14.8] [Reference Citation Analysis]
20 Daoussis D, Liossis SN. Treatment of systemic sclerosis associated fibrotic manifestations: Current options and future directions. Mediterr J Rheumatol 2019;30:33-7. [PMID: 32185340 DOI: 10.31138/mjr.30.1.33] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
21 Melissaropoulos K, Daoussis D. B cells in systemic sclerosis: from pathophysiology to treatment. Clin Rheumatol 2021;40:2621-31. [PMID: 33745085 DOI: 10.1007/s10067-021-05665-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Wenzel D, Haddadi NS, Afshari K, Richmond JM, Rashighi M. Upcoming treatments for morphea. Immun Inflamm Dis 2021. [PMID: 34272836 DOI: 10.1002/iid3.475] [Reference Citation Analysis]
23 van Laar JM. B-cell depletion with rituximab: a promising treatment for diffuse cutaneous systemic sclerosis. Arthritis Res Ther 2010;12:112. [PMID: 20441607 DOI: 10.1186/ar2977] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
24 Mcqueen FM, Solanki K. Rituximab in diffuse cutaneous systemic sclerosis: should we be using it today? Rheumatology 2015;54:757-67. [DOI: 10.1093/rheumatology/keu463] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
25 Sanges S, Jendoubi M, Kavian N, Hauspie C, Speca S, Crave JC, Guerrier T, Lefèvre G, Sobanski V, Savina A, Hachulla E, Hatron PY, Labalette M, Batteux F, Dubucquoi S, Launay D. B Cell Homeostasis and Functional Properties Are Altered in an Hypochlorous Acid-Induced Murine Model of Systemic Sclerosis. Front Immunol 2017;8:53. [PMID: 28223983 DOI: 10.3389/fimmu.2017.00053] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
26 Matsushita T, Takehara K. An update on biomarker discovery and use in systemic sclerosis. Expert Review of Molecular Diagnostics 2017;17:823-33. [DOI: 10.1080/14737159.2017.1356722] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
27 De Santis M, Ceribelli A, Cavaciocchi F, Crotti C, Massarotti M, Belloli L, Marasini B, Isailovic N, Generali E, Selmi C. Nailfold videocapillaroscopy and serum VEGF levels in scleroderma are associated with internal organ involvement. Auto Immun Highlights 2016;7:5. [PMID: 26878864 DOI: 10.1007/s13317-016-0077-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
28 Wu M, Mohan C. B-cells in systemic sclerosis: emerging evidence from genetics to phenotypes. Curr Opin Rheumatol 2015;27:537-41. [PMID: 26285102 DOI: 10.1097/BOR.0000000000000215] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
29 Giuggioli D, Lumetti F, Colaci M, Fallahi P, Antonelli A, Ferri C. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature. Autoimmunity Reviews 2015;14:1072-8. [DOI: 10.1016/j.autrev.2015.07.008] [Cited by in Crossref: 90] [Cited by in F6Publishing: 80] [Article Influence: 15.0] [Reference Citation Analysis]
30 Pendergrass SA, Lemaire R, Francis IP, Mahoney JM, Lafyatis R, Whitfield ML. Intrinsic gene expression subsets of diffuse cutaneous systemic sclerosis are stable in serial skin biopsies. J Invest Dermatol 2012;132:1363-73. [PMID: 22318389 DOI: 10.1038/jid.2011.472] [Cited by in Crossref: 98] [Cited by in F6Publishing: 93] [Article Influence: 10.9] [Reference Citation Analysis]
31 Asano Y, Jinnin M, Kawaguchi Y, Kuwana M, Goto D, Sato S, Takehara K, Hatano M, Fujimoto M, Mugii N, Ihn H. Diagnostic criteria, severity classification and guidelines of systemic sclerosis. J Dermatol 2018;45:633-91. [PMID: 29687465 DOI: 10.1111/1346-8138.14162] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
32 Furue M, Mitoma C, Mitoma H, Tsuji G, Chiba T, Nakahara T, Uchi H, Kadono T. Pathogenesis of systemic sclerosis-current concept and emerging treatments. Immunol Res 2017;65:790-7. [PMID: 28488090 DOI: 10.1007/s12026-017-8926-y] [Cited by in F6Publishing: 31] [Reference Citation Analysis]
33 Daoussis D, Antonopoulos I, Liossis SN, Yiannopoulos G, Andonopoulos AP. Treatment of systemic sclerosis-associated calcinosis: a case report of rituximab-induced regression of CREST-related calcinosis and review of the literature. Semin Arthritis Rheum 2012;41:822-9. [PMID: 22221908 DOI: 10.1016/j.semarthrit.2011.11.007] [Cited by in Crossref: 48] [Cited by in F6Publishing: 37] [Article Influence: 5.3] [Reference Citation Analysis]
34 William BM, Harbert T, Ganti AK, Bierman PJ. Small lymphocytic lymphoma in a patient with CREST syndrome. Hematol Oncol Stem Cell Ther 2011;4:132-5. [PMID: 21982887 DOI: 10.5144/1658-3876.2011.132] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
35 Hasegawa M, Takehara K. Potential immunologic targets for treating fibrosis in systemic sclerosis: a review focused on leukocytes and cytokines. Semin Arthritis Rheum 2012;42:281-96. [PMID: 22542279 DOI: 10.1016/j.semarthrit.2012.03.014] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
36 Balbir-Gurman A, Braun-Moscovici Y. Scleroderma - new aspects in pathogenesis and treatment. Best Pract Res Clin Rheumatol 2012;26:13-24. [PMID: 22424190 DOI: 10.1016/j.berh.2012.01.011] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
37 Ciechomska M, van Laar J, O'reilly S. Current frontiers in systemic sclerosis pathogenesis. Exp Dermatol 2015;24:401-6. [DOI: 10.1111/exd.12673] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
38 Misra DP, Ahmed S, Agarwal V. Is biological therapy in systemic sclerosis the answer? Rheumatol Int 2020;40:679-94. [PMID: 31960079 DOI: 10.1007/s00296-020-04515-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
39 Bruni C, Praino E, Allanore Y, Distler O, Gabrielli A, Iannone F, Matucci-Cerinic M. Use of biologics and other novel therapies for the treatment of systemic sclerosis. Expert Rev Clin Immunol 2017;13:469-82. [PMID: 27899043 DOI: 10.1080/1744666X.2017.1263153] [Cited by in Crossref: 23] [Cited by in F6Publishing: 10] [Article Influence: 4.6] [Reference Citation Analysis]
40 Abignano G, Del Galdo F. Biomarkers as an opportunity to stratify for outcome in systemic sclerosis. Eur J Rheumatol 2020;7:S193-202. [PMID: 32697933 DOI: 10.5152/eurjrheum.2020.19065] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Beyer C, Distler O, Distler JH. Innovative antifibrotic therapies in systemic sclerosis. Curr Opin Rheumatol 2012;24:274-80. [PMID: 22450392 DOI: 10.1097/BOR.0b013e3283524b9a] [Cited by in Crossref: 43] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
42 Vilela VS, Maretti GB, Gama LMDS, Costa CHD, Rufino RL, Levy RA. Rituximab for the therapy of systemic sclerosis: a series of 10 cases in a single center. Revista Brasileira de Reumatologia (English Edition) 2016;56:458-63. [DOI: 10.1016/j.rbre.2016.06.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
43 Bosello SL, De Luca G, Rucco M, Berardi G, Falcione M, Danza FM, Pirronti T, Ferraccioli G. Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. Semin Arthritis Rheum 2015;44:428-36. [PMID: 25300701 DOI: 10.1016/j.semarthrit.2014.09.002] [Cited by in Crossref: 92] [Cited by in F6Publishing: 85] [Article Influence: 13.1] [Reference Citation Analysis]
44 Pearson DR, Werth VP, Pappas-Taffer L. Systemic sclerosis: Current concepts of skin and systemic manifestations. Clin Dermatol 2018;36:459-74. [PMID: 30047430 DOI: 10.1016/j.clindermatol.2018.04.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
45 François A, Chatelus E, Wachsmann D, Sibilia J, Bahram S, Alsaleh G, Gottenberg JE. B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis. Arthritis Res Ther 2013;15:R168. [PMID: 24289101 DOI: 10.1186/ar4352] [Cited by in Crossref: 76] [Cited by in F6Publishing: 79] [Article Influence: 9.5] [Reference Citation Analysis]
46 Gale SL, Trinh H, Mathew N, Jahreis A, Lin CJF, Sarsour K. Characterizing Disease Manifestations and Treatment Patterns Among Adults with Systemic Sclerosis: A Retrospective Analysis of a US Healthcare Claims Population. Rheumatol Ther 2020;7:89-99. [PMID: 31734871 DOI: 10.1007/s40744-019-00181-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
47 Mendoza FA, Mansoor M, Jimenez SA. Treatment of Rapidly Progressive Systemic Sclerosis: Current and Futures Perspectives. Expert Opin Orphan Drugs 2016;4:31-47. [PMID: 27812432 DOI: 10.1517/21678707.2016.1114454] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
48 Blank RB, Nwawka OK, Yusov AA, Gordon JK. Inflammatory arthritis in systemic sclerosis: What to do? Journal of Scleroderma and Related Disorders 2019;4:3-16. [DOI: 10.1177/2397198318779532] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
49 Airo' P, Ceribelli A, Cavazzana I, Taraborelli M, Zingarelli S, Franceschini F. Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies. J Rheumatol 2011;38:1329-34. [PMID: 21459934 DOI: 10.3899/jrheum.101144] [Cited by in Crossref: 68] [Cited by in F6Publishing: 50] [Article Influence: 6.8] [Reference Citation Analysis]
50 Muangchan C, Pope JE. Interleukin 6 in Systemic Sclerosis and Potential Implications for Targeted Therapy. J Rheumatol 2012;39:1120-4. [DOI: 10.3899/jrheum.111423] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
51 De Lauretis A, Sestini P, Pantelidis P, Hoyles R, Hansell DM, Goh NS, Zappala CJ, Visca D, Maher TM, Denton CP, Ong VH, Abraham DJ, Kelleher P, Hector L, Wells AU, Renzoni EA. Serum Interleukin 6 Is Predictive of Early Functional Decline and Mortality in Interstitial Lung Disease Associated with Systemic Sclerosis. J Rheumatol 2013;40:435-46. [DOI: 10.3899/jrheum.120725] [Cited by in Crossref: 130] [Cited by in F6Publishing: 122] [Article Influence: 16.3] [Reference Citation Analysis]
52 Denton CP, Ong VH. Interleukin-6 and Related Proteins as Biomarkers in Systemic Sclerosis. Journal of Scleroderma and Related Disorders 2017;2:S13-9. [DOI: 10.5301/jsrd.5000266] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Tang R, Yu J, Shi Y, Zou P, Zeng Z, Tang B, Wang Y, Ling G, Luo M, Xiao R. Safety and efficacy of Rituximab in systemic sclerosis: A systematic review and meta-analysis. Int Immunopharmacol 2020;83:106389. [PMID: 32172205 DOI: 10.1016/j.intimp.2020.106389] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 14.0] [Reference Citation Analysis]
54 Daoussis D, Tsamandas AC, Liossis SN, Antonopoulos I, Karatza E, Yiannopoulos G, Andonopoulos AP. B-cell depletion therapy in patients with diffuse systemic sclerosis associates with a significant decrease in PDGFR expression and activation in spindle-like cells in the skin. Arthritis Res Ther. 2012;14:R145. [PMID: 22697462 DOI: 10.1186/ar3879] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
55 Campochiaro C, De Luca G, Lazzaroni MG, Zanatta E, Bosello SL, De Santis M, Cariddi A, Bruni C, Selmi C, Gremese E, Matucci-Cerinic M, Doria A, Airò P, Dagna L. Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study. Rheumatology (Oxford) 2020;59:3731-6. [PMID: 32413118 DOI: 10.1093/rheumatology/keaa136] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
56 Saunders P, Tsipouri V, Keir GJ, Ashby D, Flather MD, Parfrey H, Babalis D, Renzoni EA, Denton CP, Wells AU, Maher TM. Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial. Trials 2017;18:275. [PMID: 28619061 DOI: 10.1186/s13063-017-2016-2] [Cited by in Crossref: 73] [Cited by in F6Publishing: 60] [Article Influence: 18.3] [Reference Citation Analysis]
57 Smith V, Piette Y, van Praet JT, Decuman S, Deschepper E, Elewaut D, De Keyser F. Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement. J Rheumatol. 2013;40:52-57. [PMID: 23118116 DOI: 10.3899/jrheum.120778] [Cited by in Crossref: 65] [Cited by in F6Publishing: 51] [Article Influence: 7.2] [Reference Citation Analysis]
58 Erre GL, Sebastiani M, Fenu MA, Zinellu A, Floris A, Cavagna L, Renzoni E, Manfredi A, Passiu G, Woodman RJ, Mangoni AA. Efficacy, Safety, and Tolerability of Treatments for Systemic Sclerosis-Related Interstitial Lung Disease: A Systematic Review and Network Meta-Analysis. J Clin Med 2020;9:E2560. [PMID: 32784580 DOI: 10.3390/jcm9082560] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
59 Del Papa N, Zaccara E. From mechanisms of action to therapeutic application: A review on current therapeutic approaches and future directions in systemic sclerosis. Best Pract Res Clin Rheumatol 2015;29:756-69. [PMID: 27107511 DOI: 10.1016/j.berh.2016.02.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
60 Daoussis D, Melissaropoulos K, Sakellaropoulos G, Antonopoulos I, Markatseli TE, Simopoulou T, Georgiou P, Andonopoulos AP, Drosos AA, Sakkas L, Liossis SN. A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease. Semin Arthritis Rheum 2017;46:625-31. [PMID: 27839742 DOI: 10.1016/j.semarthrit.2016.10.003] [Cited by in Crossref: 102] [Cited by in F6Publishing: 87] [Article Influence: 20.4] [Reference Citation Analysis]
61 Schiopu E, Chatterjee S, Hsu V, Flor A, Cimbora D, Patra K, Yao W, Li J, Streicher K, McKeever K, White B, Katz E, Drappa J, Sweeny S, Herbst R. Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study. Arthritis Res Ther 2016;18:131. [PMID: 27267753 DOI: 10.1186/s13075-016-1021-2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
62 Yoshizaki A. Pathogenic roles of B lymphocytes in systemic sclerosis. Immunol Lett 2018;195:76-82. [PMID: 29307688 DOI: 10.1016/j.imlet.2018.01.002] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 8.7] [Reference Citation Analysis]
63 Sakkas LI, Bogdanos DP. Systemic sclerosis: New evidence re-enforces the role of B cells. Autoimmun Rev 2016;15:155-61. [PMID: 26497107 DOI: 10.1016/j.autrev.2015.10.005] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 10.2] [Reference Citation Analysis]
64 Sanges S, Guerrier T, Launay D, Lefèvre G, Labalette M, Forestier A, Sobanski V, Corli J, Hauspie C, Jendoubi M, Yakoub-Agha I, Hatron PY, Hachulla E, Dubucquoi S. Role of B cells in the pathogenesis of systemic sclerosis. Rev Med Interne 2017;38:113-24. [PMID: 27020403 DOI: 10.1016/j.revmed.2016.02.016] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
65 Zekovic A, Vreca M, Spasovski V, Andjelkovic M, Pavlovic S, Damjanov N. Association between the -174 C/G polymorphism in the interleukin-6 (IL-6) gene and gastrointestinal involvement in patients with systemic sclerosis. Clin Rheumatol 2018;37:2447-54. [DOI: 10.1007/s10067-018-4163-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
66 De Luca G, Campochiaro C, Sartorelli S, Peretto G, Dagna L. Therapeutic strategies for virus-negative myocarditis: a comprehensive review. European Journal of Internal Medicine 2020;77:9-17. [DOI: 10.1016/j.ejim.2020.04.050] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
67 Boonstra M, Meijs J, Dorjée AL, Marsan NA, Schouffoer A, Ninaber MK, Quint KD, Bonte-Mineur F, Huizinga TWJ, Scherer HU, de Vries-Bouwstra JK. Rituximab in early systemic sclerosis. RMD Open 2017;3:e000384. [PMID: 28879049 DOI: 10.1136/rmdopen-2016-000384] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
68 Caldas MMVF, Neto FAB, Azevedo KPM, Pimenta IDSF, Oliveira AKDSG, Piuvezam G. Rituximab in systemic sclerosis: A protocol for systematic review. Medicine (Baltimore) 2019;98:e17110. [PMID: 31567948 DOI: 10.1097/MD.0000000000017110] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
69 Fuschiotti P. Current perspectives on the immunopathogenesis of systemic sclerosis. Immunotargets Ther 2016;5:21-35. [PMID: 27529059 DOI: 10.2147/ITT.S82037] [Cited by in Crossref: 37] [Cited by in F6Publishing: 18] [Article Influence: 7.4] [Reference Citation Analysis]
70 Becker MO. [Systemic sclerosis : What is currently available for treatment?]. Internist (Berl) 2016;57:1155-63. [PMID: 27796473 DOI: 10.1007/s00108-016-0148-1] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
71 Rath E, Zwerina J, Oppl B, Nell-duxneuner V. Efficacy and safety of rituximab in rheumatic diseases. Wien Med Wochenschr 2015;165:28-35. [DOI: 10.1007/s10354-014-0331-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
72 Melissaropoulos K, Liossis SN. Decreased CD22 expression and intracellular signaling aberrations in B cells of patients with systemic sclerosis. Rheumatol Int 2018;38:1225-34. [PMID: 29869007 DOI: 10.1007/s00296-018-4076-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
73 Eldoma M, Pope J. The contemporary management of systemic sclerosis. Expert Rev Clin Immunol 2018;14:573-82. [PMID: 29874475 DOI: 10.1080/1744666X.2018.1485490] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
74 Viswanath V, Phiske MM, Gopalani VV. Systemic sclerosis: current concepts in pathogenesis and therapeutic aspects of dermatological manifestations. Indian J Dermatol 2013;58:255-68. [PMID: 23918994 DOI: 10.4103/0019-5154.113930] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
75 Bosello S, Angelucci C, Lama G, Alivernini S, Proietti G, Tolusso B, Sica G, Gremese E, Ferraccioli G. Characterization of inflammatory cell infiltrate of scleroderma skin: B cells and skin score progression. Arthritis Res Ther 2018;20:75. [PMID: 29669578 DOI: 10.1186/s13075-018-1569-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
76 Werner A, Schäfer S, Zaytseva O, Albert H, Lux A, Krištić J, Pezer M, Lauc G, Winkler T, Nimmerjahn F. Targeting B cells in the pre-phase of systemic autoimmunity globally interferes with autoimmune pathology. iScience 2021;24:103076. [PMID: 34585117 DOI: 10.1016/j.isci.2021.103076] [Reference Citation Analysis]
77 Huang E, Peng N, Xiao F, Hu D, Wang X, Lu L. The Roles of Immune Cells in the Pathogenesis of Fibrosis. Int J Mol Sci 2020;21:E5203. [PMID: 32708044 DOI: 10.3390/ijms21155203] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
78 Melissaropoulos K, Kraniotis P, Bogdanos D, Dimitroulas T, Sakkas L, Daoussis D. Targeting very early systemic sclerosis: a case-based review. Rheumatol Int 2019;39:1961-70. [PMID: 31254002 DOI: 10.1007/s00296-019-04357-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
79 Xing NS, Fan GZ, Yan F, Liu YP, Zhang R. Safety and efficacy of rituximab in connective tissue disease-associated interstitial lung disease: A systematic review and meta-analysis. Int Immunopharmacol 2021;95:107524. [PMID: 33721757 DOI: 10.1016/j.intimp.2021.107524] [Reference Citation Analysis]
80 Vicente-Rabaneda EF, Serra López-Matencio JM, Ancochea J, Blanco R, González-Gay MÁ, Castañeda S. Efficacy and safety of biological drugs in interstitial lung disease associated with connective tissue diseases. Expert Opin Drug Saf 2021;:1-23. [PMID: 34433372 DOI: 10.1080/14740338.2021.1973428] [Reference Citation Analysis]
81 De Luca G, Tomelleri A, Dagna L, Matucci-Cerinic M. The target on B cells in Systemic Sclerosis: a "midsummer dream" to extinguish inflammation and prevent early disease progression to fibrosis. Clin Rheumatol 2021;40:2529-33. [PMID: 34021841 DOI: 10.1007/s10067-021-05733-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
82 Leask A. B cell block: is rituximab a new possible treatment for systemic sclerosis? J Cell Commun Signal 2010;4:201-2. [PMID: 21234128 DOI: 10.1007/s12079-010-0107-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
83 Melsens K, Vandecasteele E, Deschepper E, Badot V, Blockmans D, Brusselle G, De Langhe E, De Pauw M, Debusschere C, Decuman S, Deroo L, Houssiau F, Lenaerts J, Piette Y, Thevissen K, Vanthuyne M, Westhovens R, Wijnant S, De Keyser F, Smith V. Two years follow-up of an open-label pilot study of treatment with rituximab in patients with early diffuse cutaneous systemic sclerosis. Acta Clinica Belgica 2018;73:119-25. [DOI: 10.1080/17843286.2017.1372244] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
84 Sakkas LI, Simopoulou T, Katsiari C, Bogdanos D, Chikanza IC. Early systemic sclerosis—opportunities for treatment. Clin Rheumatol 2015;34:1327-31. [DOI: 10.1007/s10067-015-2902-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
85 Bellan M, Patrucco F, Barone-adesi F, Gavelli F, Castello LM, Nerviani A, Andreoli L, Cavagna L, Pirisi M, Sainaghi PP. Targeting CD20 in the treatment of interstitial lung diseases related to connective tissue diseases: A systematic review. Autoimmunity Reviews 2020;19:102453. [DOI: 10.1016/j.autrev.2019.102453] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 15.0] [Reference Citation Analysis]
86 Schioppo T, Ingegnoli F. Current perspective on rituximab in rheumatic diseases. Drug Des Devel Ther 2017;11:2891-904. [PMID: 29042750 DOI: 10.2147/DDDT.S139248] [Cited by in Crossref: 46] [Cited by in F6Publishing: 17] [Article Influence: 11.5] [Reference Citation Analysis]
87 Daoussis D, Andonopoulos AP. B cell depletion in scleroderma lung disease: A promising new treatment? World J Rheumatol 2013; 3(2): 9-11 [DOI: 10.5499/wjr.v3.i2.9] [Reference Citation Analysis]
88 Haroon M, McLaughlin P, Henry M, Harney S. Cyclophosphamide-refractory scleroderma-associated interstitial lung disease: remarkable clinical and radiological response to a single course of rituximab combined with high-dose corticosteroids. Ther Adv Respir Dis 2011;5:299-304. [PMID: 21593063 DOI: 10.1177/1753465811407786] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
89 Sierra-Sepúlveda A, Esquinca-González A, Benavides-Suárez SA, Sordo-Lima DE, Caballero-Islas AE, Cabral-Castañeda AR, Rodríguez-Reyna TS. Systemic Sclerosis Pathogenesis and Emerging Therapies, beyond the Fibroblast. Biomed Res Int 2019;2019:4569826. [PMID: 30809542 DOI: 10.1155/2019/4569826] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 13.5] [Reference Citation Analysis]
90 Dumoitier N, Chaigne B, Régent A, Lofek S, Mhibik M, Dorfmüller P, Terrier B, London J, Bérezné A, Tamas N, Varin‐blank N, Mouthon L. Scleroderma Peripheral B Lymphocytes Secrete Interleukin‐6 and Transforming Growth Factor β and Activate Fibroblasts. Arthritis & Rheumatology 2017;69:1078-89. [DOI: 10.1002/art.40016] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
91 Coustet B, Dieudé P, Guedj M, Bouaziz M, Avouac J, Ruiz B, Hachulla E, Diot E, Cracowski J, Tiev K, Sibilia J, Mouthon L, Frances C, Amoura Z, Carpentier P, Cosnes A, Meyer O, Kahan A, Boileau C, Chiocchia G, Allanore Y. C8orf13-BLK is a genetic risk locus for systemic sclerosis and has additive effects with BANK1: Results from a large french cohort and meta-analysis. Arthritis & Rheumatism 2011;63:2091-6. [DOI: 10.1002/art.30379] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 3.8] [Reference Citation Analysis]
92 Ebata S, Yoshizaki A, Fukasawa T, Miura S, Takahashi T, Sumida H, Asano Y, Sato S. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease. J Dermatol 2019;46:1006-13. [PMID: 31502326 DOI: 10.1111/1346-8138.15079] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
93 Eckes B, Moinzadeh P, Sengle G, Hunzelmann N, Krieg T. Molecular and cellular basis of scleroderma. J Mol Med 2014;92:913-24. [DOI: 10.1007/s00109-014-1190-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
94 Sircar G, Goswami RP, Sircar D, Ghosh A, Ghosh P. Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. Rheumatology 2018;57:2106-13. [DOI: 10.1093/rheumatology/key213] [Cited by in Crossref: 83] [Cited by in F6Publishing: 62] [Article Influence: 27.7] [Reference Citation Analysis]
95 Thiebaut M, Launay D, Rivière S, Mahévas T, Bellakhal S, Hachulla E, Fain O, Mekinian A. Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review. Autoimmunity Reviews 2018;17:582-7. [DOI: 10.1016/j.autrev.2017.12.010] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 17.0] [Reference Citation Analysis]
96 Elhai M, Boubaya M, Distler O, Smith V, Matucci-Cerinic M, Alegre Sancho JJ, Truchetet ME, Braun-Moscovici Y, Iannone F, Novikov PI, Lescoat A, Siegert E, Castellví I, Airó P, Vettori S, De Langhe E, Hachulla E, Erler A, Ananieva L, Krusche M, López-Longo FJ, Distler JHW, Hunzelmann N, Hoffmann-Vold AM, Riccieri V, Hsu VM, Pozzi MR, Ancuta C, Rosato E, Mihai C, Kuwana M, Saketkoo LA, Chizzolini C, Hesselstrand R, Ullman S, Yavuz S, Rednic S, Caimmi C, Bloch-Queyrat C, Allanore Y; for EUSTAR network. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. Ann Rheum Dis 2019;78:979-87. [PMID: 30967395 DOI: 10.1136/annrheumdis-2018-214816] [Cited by in Crossref: 69] [Cited by in F6Publishing: 58] [Article Influence: 34.5] [Reference Citation Analysis]
97 Lóránd V, Czirják L, Minier T. Musculoskeletal involvement in systemic sclerosis. Presse Med 2014;43:e315-28. [PMID: 25179276 DOI: 10.1016/j.lpm.2014.03.027] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
98 Daoussis D, Liossis SN, Yiannopoulos G, Andonopoulos AP. B-cell depletion therapy in systemic sclerosis: experimental rationale and update on clinical evidence. Int J Rheumatol. 2011;2011:214013. [PMID: 21826145 DOI: 10.1155/2011/214013] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
99 Antic M, Distler JH, Distler O. Treating skin and lung fibrosis in systemic sclerosis: a future filled with promise? Curr Opin Pharmacol 2013;13:455-62. [PMID: 23747024 DOI: 10.1016/j.coph.2013.05.016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
100 Berghen N, Vulsteke JB, Westhovens R, Lenaerts J, De Langhe E. Rituximab in systemic autoimmune rheumatic diseases: indications and practical use. Acta Clin Belg 2019;74:272-9. [PMID: 30253707 DOI: 10.1080/17843286.2018.1521904] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
101 Panopoulos ST, Sfikakis PP. Biological treatments and connective tissue disease associated interstitial lung disease. Curr Opin Pulm Med 2011;17:362-7. [PMID: 21597375 DOI: 10.1097/MCP.0b013e3283483ea5] [Cited by in Crossref: 37] [Cited by in F6Publishing: 12] [Article Influence: 4.1] [Reference Citation Analysis]